In Vitro Diagnostics Quality Control Market worth $1,158 Million by 2025
According to research report the global In Vitro Diagnostics Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.
Some of the factors driving the growth of the In Vitro Diagnostics
Quality Control Market are increasing number of accredited clinical
laboratories, rising demand for external quality assurance support, and
growing adoption of third-party quality controls.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582
The North America is expected to account for the largest share of the
global IVD quality control market in 2020, followed by Europe. The large
share of the North America can be attributed to the highly developed
healthcare system in the US and Canada, and the presence of a large
number of leading IVD quality control vendors & national clinical
laboratories & hospitals in this region.
Based on
applications, the In Vitro Diagnostics Quality Control Market is
segmented into clinical chemistry, immunochemistry, hematology,
coagulation & hemostasis, microbiology, molecular diagnostics, and
other applications (ESR, urine chemistry, immunology, cardiac
assessment, and blood morphology). The molecular diagnostics segment is
expected to grow at the highest CAGR during the forecast period. This
growth can be attributed to the rising prevalence of infectious
diseases, cancer, and various genetic disorders; the growing demand for
blood screening; and the increasing application of molecular diagnostic
technologies in pharmacogenetics and point-of-care testing.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582
On the basis of type, the quality control products market is segmented
into serum/plasma-based controls, whole blood-based controls,
urine-based controls, and other controls (controls manufactured from
spinal fluid, lipoprotein extracts, and immunoproteins). The
serum/plasma-based controls segment is expected to account for the
largest market share in 2019. The large share of this segment is mainly
attributed to the greater uptake of serum/plasma-based quality controls
among laboratories and the widening application areas of these controls
for various IVD tests.
The prominent players in this In Vitro
Diagnostics Quality Control Market are Bio-Rad Laboratories Inc. (US),
Randox Laboratories Ltd. (UK), Thermo Fisher Scientific Inc. (US),
Technopath Clinical Diagnostics (Ireland), Bio-Techne Corporation (US),
Fortress Diagnostics (UK), SeraCare Life Sciences Inc. (US), SERO AS
(Norway), Roche Diagnostics (Switzerland), Siemens Healthineers
(Germany), Danaher Corporation (US), and Abbott Laboratories Inc. (US).
Bio-Rad Laboratories Inc. (US) was the leading player in the In Vitro
Diagnostics Quality Control Market and accounted for the largest share
in 2018. The company is a leading provider of clinical diagnostic
systems, analytical devices, and instruments. The company has a robust
portfolio of quality control products, data management solutions and
quality assurance services for hospital laboratories, reference
laboratories, transfusion laboratories, and physician office
laboratories.
Comments
Post a Comment